HC Wainwright Brokers Reduce Earnings Estimates for Innoviva

Innoviva, Inc. (NASDAQ:INVA) – Equities researchers at HC Wainwright lowered their Q3 2026 EPS estimates for Innoviva in a research note issued to investors on Monday, June 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn $0.50 per share for the quarter, down from their prior estimate of $0.51. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Innoviva’s FY2026 earnings at $2.20 EPS.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. Innoviva had a return on equity of 33.33% and a net margin of 119.89%.The firm had revenue of $97.99 million during the quarter, compared to analysts’ expectations of $101.57 million.

Several other brokerages have also recently commented on INVA. Wall Street Zen raised Innoviva from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a research report on Friday, March 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $42.00 target price on shares of Innoviva in a research note on Monday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Innoviva presently has a consensus rating of “Moderate Buy” and an average target price of $36.20.

Innoviva Stock Performance

Shares of INVA stock opened at $23.57 on Wednesday. Innoviva has a fifty-two week low of $16.52 and a fifty-two week high of $25.15. The stock’s 50-day moving average is $22.75 and its two-hundred day moving average is $21.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 21.13 and a quick ratio of 20.07. The firm has a market cap of $1.74 billion, a P/E ratio of 3.92 and a beta of 0.35.

Institutional Trading of Innoviva

Large investors have recently made changes to their positions in the stock. Parallel Advisors LLC increased its holdings in shares of Innoviva by 82.8% during the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 534 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Innoviva by 297.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,795 shares during the last quarter. Danske Bank A S bought a new stake in Innoviva during the third quarter worth approximately $55,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Innoviva by 49.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 1,197 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Innoviva during the second quarter valued at approximately $92,000. Institutional investors own 99.12% of the company’s stock.

Key Innoviva News

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Innoviva and set a $42 price target, reinforcing a bullish longer-term view on the shares.
• Positive Sentiment: Innoviva Specialty Therapeutics partnered with Dr. Reddy’s to expand XACDURO access internationally, which could broaden the product’s reach and support future revenue growth. Article: Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
• Neutral Sentiment: HC Wainwright kept a Buy rating and $46 price target, but trimmed estimates across multiple periods, including Q3 2026 EPS to $0.50 from $0.51 and FY2026 EPS to $2.20 from $2.23, signaling only modest near-term caution rather than a major change in outlook.
• Neutral Sentiment: The same firm also lowered longer-dated projections slightly, including Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, and FY2027 EPS, but the revisions were small and still accompanied by an upbeat rating.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin?out transaction in 2014, separating the royalty assets from a research?based biopharmaceutical enterprise to create a specialized investment vehicle.